Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome
from Latest Results for PharmacoEconomics at http://bit.ly/1rOjUu4 on August 01, 2014 at 01:00AM Abstract Background Acute coronary syndrome (ACS) represents the most common subset of cardiovascular heart diseases and relates to high rates of morbidity and mortality worldwide and, consequently, to both the direct and indirect costs to the health system and society. Given the […]
You must be logged in to post a comment.